Category Archives: Food & Drug Recalls

Maytag Dairy Farms Blue Cheese Sold at 17 Select Schnuck Markets Recalled Due to Possible Health Risk

Maytag Blue Cheese has been voluntarily recalled from 17 Schnuck Markets locations due to possible contamination with Listeria monocytogenes. The potential for contamination was discovered after testing by the State of Iowa at Maytag Dairy Farms, Inc., Newton Iowa, revealed the presence of Listeria monocytogenes.
Read The Complete Story!

Loki Fish Company Recalls Smoked Pink Salmon Because of Possible Health Risk

Loki Fish Company of Seattle, WA is voluntarily recalling two lots of Wild Smoked Pink Salmon Portions, due to a positive test result for Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, listeria infection can cause miscarriages and stillbirths among pregnant women.

BI-LO Store in Glennville, GA Recalls Cantaloupes Due to Potential Health Risk

BI-LO, LLC, today announced an immediate recall for one BI-LO store in Glennville, GA (#5744) for fresh products containing cantaloupe, because they have the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, Listeria infection can cause miscarriages and stillbirths among pregnant women.

FDA and DOJ take action against Virginia soybean business for selling contaminated sprouts

Today, the United States District Court for the Eastern District of Virginia entered a consent decree of permanent injunction between the United States and Henry’s Farm, Inc., located in Woodford, Virginia, and its owner Soo C. Park, after the U.S. Food and Drug Administration documented multiple violations of federal food safety laws and regulations. The consent decree prohibits Henry’s Farm, Inc. from receiving, processing, manufacturing, preparing, packing, holding and distributing ready-to-eat soybean and mung-bean sprouts. The U.S. Department of Justice sought the consent decree on behalf of the FDA.

FDA Investigates Multistate Outbreak of Salmonella Muenchen Linked to Alfalfa Sprouts Produced by Sweetwater Farms

The FDA, CDC, state and local officials are investigating a multi-state outbreak of Salmonella Muenchen illnesses linked to alfalfa sprouts produced by Sweetwater Farms LLC, Inman, Kansas.

The CDC reports that 13 people were infected with the outbreak strains of Salmonella Muenchen in four states: Kansas (5), Missouri (3), Oklahoma (3), and Pennsylvania (2). Five people have been hospitalized. Reported illness onset dates range from December 1, 2015 through January 21, 2016.

FDA issues recommendations to reduce the risk of Zika virus transmission by human cell and tissue products

As an additional safety measure against the emerging Zika virus outbreak, the U.S. Food and Drug Administration today issued new guidance for immediate implementation providing recommendations to reduce the potential transmission risk of Zika virus from human cells, tissues, and cellular and tissue-based products (HCT/Ps). The guidance addresses donation of HCT/Ps from both living and deceased donors, including donors of umbilical cord blood, placenta, or other gestational tissues.

FDA takes additional action to better understand safety of Essure, inform patients of potential risks

The U.S. Food and Drug Administration announced today two actions to provide important information about the risks of using Essure and to help women and their doctors be better informed of the potential complications associated with implantable forms of sterilization. These actions include a new, mandatory clinical study for Essure to determine heightened risks for particular women and draft guidance with labeling recommendations including a boxed warning label and a checklist for doctors to discuss potential risks of implanted permanent birth control devices with patients. Since Essure’s approval in 2002, the agency has continued to monitor Essure’s safety and effectiveness by reviewing the medical literature, clinical trial information, post-approval study data and medical device reports submitted to the agency. The new actions announced today take additional steps and follow the agency’s careful evaluation of available information.